pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Aqneursa
drug · small molecule
save

levacetylleucine

Marketedupdated 6mo ago
by IntraBio Ltd🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for niemann-pick disease type c and 3 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying levacetylleucine

  • —Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)approved for marketing

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 24, 2029
~2.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Apr 19, 2037method-of-use (U-4170)US 11400067
  • Apr 19, 2037method-of-use (U-4284)US 12433862
  • Apr 19, 2037method-of-use (U-4285)US 12433863

FDA exclusivities (2)

  • Sep 24, 2031ODE-498Orphan Drug (7y)4.9y
  • Sep 24, 2029NCENew Chemical Entity (5y)2.9y

News(5)

  • Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
    biospace · 1mo ago
  • Shionogi makes $2B rare disease play with IntraBio buy
    With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…
    biospace · 1mo ago
  • Shionogi pays $2B to acquire a rare disease startup
    The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.
    biopharma_dive · 1mo ago
  • Shionogi to pay $2B for IntraBio, a commercial rare disease biotech
    Shionogi is buying an Austin, TX-based commercial biotech for $2 billion upfront, adding another medicine to the Japanese pharma's rare disease portfolio. The drugmaker is scooping up IntraBio and…
    endpoints · 1mo ago
  • FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
    Plus news about Biokin, Bristol Myers Squibb, Grünenthal and Johnson & Johnson. FDA approves ataxia-telangiectasia treatment: The agency approved the rare genetic disease treatment Aqneursa from th…
    endpoints · 1mo ago
brand
Aqneursa
trade names
Aqneursa
generic
levacetylleucine
indication
Ataxia-Telangiectasia (Louis-Bar Syndrome)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?